RODRIGUEZ MORENO, C. et al. Use of betablockers on treatment of cardiac failure. []. , 19, 7, pp.50-56. ISSN 0212-7199.

The rationale for betablocker use in heart failure, based on neurohormonal physiology, has been established over the past 20 years. Recent trials have shown the unequivocal benefits of betablockers in patients with chronic systolic heart failure. The benefits include improve survival (35%) reduced need for hospitalization and improve of left ventricular function. However, betablockers may also make a patient with heart failure worse, especially when treatment begins and there is reluctance to use betablockade therapy. Complications can generally be avoided by starting with extremely low doses and increasing the dose very slowly. Despite this, further questions remain regarding the use of these agents in cardiac failure, including the role in the progresión of the disease, the selection of individual betablocker, and the use in very severe disease or very old patients. 

: Cardiac failure; Betablocker; Drug treatment.

        · |     · |     · ( pdf )